Your browser doesn't support javascript.
loading
Neurological phenotype of adenosine deaminase 2 deficient patients: a cohort study.
Verschoof, Merelijne A; van Meenen, Laura C C; Andriessen, M Valérie E; Brinkman, Daniëlle M C; Kamphuis, Sylvia; Kuijpers, Taco W; Leavis, Helen L; Legger, G Elizabeth; Mulders-Manders, Catharina M; de Pagter, Anne P J; Rutgers, Abraham; van Well, Gijs T J; Coutinho, Jonathan M; Hak, A Elisabeth; van Montfrans, Joris M; Klouwer, Femke C C.
Affiliation
  • Verschoof MA; Department of Neurology, HagaZiekenhuis, The Hague, The Netherlands.
  • van Meenen LCC; Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Andriessen MVE; Department of Pediatric Immunology and Infectious Diseases, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Brinkman DMC; Department of Pediatrics, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands.
  • Kamphuis S; Department of Pediatric Rheumatology, Sophia Children's Hospital, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Kuijpers TW; Department of Pediatric Immunology and Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Leavis HL; Department of Rheumatology and Clinical Immunology, University Medical Center and Utrecht University, Utrecht, The Netherlands.
  • Legger GE; Department of Pediatric Rheumatology and Immunology, University Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Mulders-Manders CM; Department of Internal Medicine, Radboud Expertise Center for Immunodeficiency and Autoinflammation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • de Pagter APJ; Department of Pediatrics, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands.
  • Rutgers A; Department of Rheumatology and Clinical Immunology, University Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • van Well GTJ; Division of Pediatric Infectious Diseases, Immunology & Rheumatology, Department of Pediatrics, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Coutinho JM; Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Hak AE; Departments of Internal Medicine and Rheumatology and Clinical Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • van Montfrans JM; Department of Pediatric Immunology and Infectious Diseases, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Klouwer FCC; Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Eur J Neurol ; 31(1): e16043, 2024 01.
Article in En | MEDLINE | ID: mdl-37584090
ABSTRACT
BACKGROUND AND

PURPOSE:

Patients with adenosine deaminase 2 (ADA2) deficiency can present with various neurological manifestations due to vasculopathies and autoinflammation. These include ischaemic and hemorrhagic stroke, but less clearly defined neurological symptoms have also been reported.

METHODS:

In this cohort study, patients with confirmed ADA2 deficiency from seven university hospitals in the Netherlands were included. The frequency and recurrence rates of neurological manifestations before and after initiation of tumor necrosis factor α (TNF-α) inhibiting therapy were analyzed.

RESULTS:

Twenty-nine patients were included with a median age at presentation of 5 years (interquartile range 1-17). Neurological manifestations occurred in 19/29 (66%) patients and were the presenting symptom in 9/29 (31%) patients. Transient ischaemic attack (TIA)/ischaemic stroke occurred in 12/29 (41%) patients and was the presenting symptom in 8/29 (28%) patients. In total, 25 TIAs/ischaemic strokes occurred in 12 patients, one after initiation of TNF-α inhibiting therapy and one whilst switching between TNF-α inhibitors. None was large-vessel occlusion stroke. Two hemorrhagic strokes occurred one aneurysmatic subarachnoid hemorrhage and one spontaneous intracerebral hemorrhage. Most neurological symptoms, including cranial nerve deficits, vertigo, ataxia and seizures, were caused by TIAs/ischaemic strokes and seldom recurred after initiation of TNF-α inhibiting therapy.

CONCLUSIONS:

Neurological manifestations, especially TIA/ischaemic stroke, are common in patients with ADA2 deficiency and frequently are the presenting symptom. Because it is a treatable cause of young stroke, for which antiplatelet and anticoagulant therapy are considered contraindicated, awareness amongst neurologists and pediatricians is important. Screening for ADA2 deficiency in young patients with small-vessel ischaemic stroke without an identified cause should be considered.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Ischemia / Ischemic Attack, Transient / Stroke / Ischemic Stroke Type of study: Etiology_studies / Observational_studies / Prognostic_studies Limits: Child, preschool / Humans Language: En Journal: Eur J Neurol / Eur. j. neurol / European journal of neurology Journal subject: NEUROLOGIA Year: 2024 Type: Article Affiliation country: Netherlands

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Ischemia / Ischemic Attack, Transient / Stroke / Ischemic Stroke Type of study: Etiology_studies / Observational_studies / Prognostic_studies Limits: Child, preschool / Humans Language: En Journal: Eur J Neurol / Eur. j. neurol / European journal of neurology Journal subject: NEUROLOGIA Year: 2024 Type: Article Affiliation country: Netherlands